Skip to main content

Life Sciences


From biotech startups to big pharma, we follow the science.
Our team speaks the same language as our clients do, and helps them navigate the product life cycle – from M&A to patent and product liability proceedings. Working together, at every stage, to bring new products to market and protect your assets.
Subscribe Fasken
Share
  • LinkedIn

Overview

The lawyers at Fasken work with clients throughout the product life cycle and at every level of involvement. We have the scientific backgrounds and respected experience to provide strategic advice in almost any situation where it is needed.

By collaborating with colleagues who know the specific regulatory, marketing, intellectual property, competition, tax, litigation and business law matters unique to life sciences, we create multi-disciplinary solutions that protect client interests as their products move from conception to consumer or clinical use.

 

Our clients range from start-up biotech companies to the biggest pharmaceutical. We also work with clients from the  medical devices, natural health product (NHP), cosmetic, cannabis, veterinary, and human tissues. We help all life sciences industry stakeholders, including manufacturers, distributors, hospitals, pharmacies, retailers, academic and financial institutions and third-party research organizations.

 

Your team at Fasken includes lawyers with advance degrees in pharmaceutical sciences, clinical pharmacology, toxicology and genetics with a strong network of life sciences experts in 47 countries across the globe. We are committed to leadership in life sciences law; we write the leading guide to legal and regulatory regimes governing the manufacture and sale of drugs, medical devices and cosmetics in Canada and give frequent presentations to client organizations and associations. We’ve also been honored by respected organizations including Chambers, LMG Life Sciences, Who’s Who Legal, among others for innovative work year after year.

 

Read our publications, browse some of our recent life sciences work we’ve assisted with or contact any of our lawyers to learn more. 

Areas of Expertise

  • Agreements and Outsourcing, Fasken’s life science team creates the right contractual and pre-contractual documentation to protect your position and specify requirements. We do this for every type of agreement, whether you’re establishing preferred suppliers, tendering, drafting confidentiality agreements or negotiating final terms.
  • Biomedical Technologies, From rapid technological advancements to complex regulatory requirements, we know the impact you’re making doesn’t come without challenges. We’ll help clear the obstacles to build a better tomorrow.
  • Capital Raising and M&A in Life Sciences, Fasken combines respected securities law experience with life sciences acumen to bring unique value to our clients who want to cost-effectively raise capital and complete deals that advance their goals.
  • Litigation in Life Sciences, Our litigation group works with our life sciences clients to identify, reduce and manage their legal risks, and when litigation occurs, to help achieve successful and cost-efficient solutions.
  • Regulatory Affairs in Life Sciences, Fasken delivers practical solutions and strategic advice to meet the unique regulatory considerations that our life sciences clients must contend with at every stage of the product lifecycle.

Achievements

Team

Primary Contacts
  • Timothy M. Squire, Partner | CO-LEADER, LIFE SCIENCES, Toronto, ON, +1 416 868 3462, tsquire@fasken.com
  • Mathieu Gagné, Partner | Co-Leader, Life Sciences, Montréal, QC, +1 514 397 7657, mgagne@fasken.com
  • Peter J. Pliszka, Partner | CHAIR, LIFE SCIENCES LITIGATION | CHAIR, PRODUCT LIABILITY & INSURANCE GROUP, Toronto, ON, +1 416 868 3336, ppliszka@fasken.com
  • Sylvie Bourdeau, Partner, Montréal, QC, +1 514 397 4388, sbourdeau@fasken.com
  • Ludwig Frahm-Arp, Partner, Johannesburg, +27 11 586 6060, lfrahm-arp@fasken.com
  • Tracy L. Hooey, Partner, Toronto, ON, +1 416 868 3439, thooey@fasken.com
  • Ingrid E. VanderElst, PhD, Partner | Trademark Agent, Toronto, ON, +1 416 865 4519, ivanderelst@fasken.com
  • Roger A.C. Kuypers, Partner | Trademark Agent, Vancouver, BC, +1 604 631 4880, rkuypers@fasken.com
  • Dara Jospé, Partner, Montréal, QC, +1 514 397 7649, djospe@fasken.com
  • Jean-Raphaël Champagne, Partner, Québec, QC, +1 418 640 2084, jchampagne@fasken.com

Client Work

  • CWB Maxium Financial Inc. provides financing for Grey Wolf Animal Health Corp.'s C$22.5 million acquisition of The Compounding Pharmacy of Manitoba, [Deal - CWB Maxium Financial Inc.], CWB Maxium Financial Inc. provided acquisition financing to Grey Wolf Animal Health Corp. to facilitate its C$22.5 million acquisition of The Compounding Pharmacy of Manitoba.
  • Dimension Capital leads Aspect Biosystems in raising US$115 million series B financing to advance bioprinted tissue therapeutics, [Deal - Dimension Capital], US$115 million series B financing in biotech industry
  • HDAX Therapeutics Inc. secures US$3.2 million in seed financing, [Deal - HDAX Therapeutics Inc.]
  • Radiant Biotherapeutics secured USD $35 million Series A financing, [Deal - Amplitude Ventures], Radiant Biotherapeutics closes USD $35 million Series A funding.
  • Ability Biologics closes its US$18 million seed funding round, [Deal - Ability Biologics], Ability Biologics closes seed funding round.
  • Catalera BioSolutions Inc., a pioneering innovator in biological pest control solutions, in its USD $6.5 million Series A funding round, [Deal - Catalera BioSolutions Inc.], Series A funding for Catalera
  • Kardium raises USD $104 million financing round, [Deal - Kardium Inc.], New private financing round in Technology industry
  • Acorn Biolabs Inc. closes US$8 million Series A funding round led by Merz Aesthetics, [Deal - Acorn Biolabs Inc.], Canada-based personalized regenerative medicine company receives funding from leading dedicated medical aesthetics business.
  • ViewsML is transforming spatial biology for translational research and precision medicine using AI deep learning, in its seed funding round, [Deal - ViewsML Technologies Inc.], Seed financing in Tech industry

Knowledge

Events

News

    Subscribe

    Receive email updates from our team

    Subscribe